Corporate presentation
Logotype for ALX Oncology Holdings Inc

ALX Oncology (ALXO) Corporate presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for ALX Oncology Holdings Inc

Corporate presentation summary

16 Nov, 2026

Strategy and catalysts

  • Two programs, evorpacept and ALX2004, target multiple development inflection points in 2026–2027.

  • ASPEN-09 is enrolling 120 patients with HER2+ metastatic breast cancer after ENHERTU; topline data are anticipated in 2H 2027.

  • ALX2004 Phase 1 safety and early efficacy results from approximately 40 patients are expected in December 2026.

Evorpacept clinical evidence

  • In ASPEN-06 retained HER2+ gastric cancer, CD47-high patients had ORR of 65% with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.1% with control.

  • ASPEN-06 CD47-high patients had median PFS of 18.4 months with evorpacept combination versus 7.0 months with control; HR 0.39 (95% CI 0.17–0.86).

  • In HER2+ breast cancer, CD47-high patients receiving evorpacept plus zanidatamab had median PFS of 22.1 months versus 3.4 months in CD47-low patients.

  • ASPEN-06 showed comparable any-cause adverse-event incidence between arms; evorpacept has been studied in >750 patients, with a generally manageable and reversible safety profile.

ALX2004 development

  • ALX2004 is an EGFR-targeted ADC with a matuzumab-derived antibody, proprietary linker and DAR 8 topoisomerase I inhibitor payload.

  • Preclinical studies reported dose-dependent activity across tumors and EGFR levels; NHP studies found no evidence of ILD or major dose-limiting target-organ toxicity.

  • Phase 1 dose escalation is evaluating EGFR-expressing NSCLC, HNSCC, CRC and ESCC; expansion could assess selected tumor types and dose schedules.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ALX Oncology